Special contributionAdult Mesenchymal Stem Cells: Biological Properties, Characteristics, and Applications in Maxillofacial Surgery
Section snippets
Background
Bone marrow (BM) is a complex, heterogeneous cellular milieu comprised of HSCs, adipocytes, osteoblasts, endothelial cells, smooth muscle cells, and MSCs. BM was traditionally recognized for its role in hematopoiesis.30 In a pioneering study conducted over 30 years ago, Friedenstein et al31 proposed that BM of postnatal organisms contained adherent fibroblastic cells capable of giving rise to bone and cartilage-like colonies. Originally named “colony forming unit-fibroblast (CFU-F),” these
Cell-Based Tissue Engineering
Tissue deficiencies in the maxillofacial region most frequently arise as a result of postcancer ablative surgery, infection, trauma, deforming skeletal diseases, or congenital malformations,67, 68 leaving the reconstructive surgeon with the great challenge of repairing the defects with the use of alloplastic materials or limited autogenous tissues, each of which with inherent limitations, including hemorrhage, nerve damage, cosmetic disability, pain, infection, and loss of function.69 Tissue
Craniofacial Skeleton
The repair of bony defects in the craniofacial skeleton is a major challenge in maxillofacial surgery, for traditional grafting techniques require substantial time and effort with associated risk of morbidity. The issue of bone regeneration is at the forefront of current tissue engineering applications.43 To date a number of delivery vehicles (eg, porous ceramics of hydroxyapatite, and β-tricalcium phosphate) loaded with MSCs have been employed to heal critical-sized segmental bone defects.85
Future Directions
Multipotent MSCs derived from adult tissues present an exciting cell source for applications in the regeneration of tissues in the maxillofacial region. Future therapeutic modalities using MSCs may include direct implantation and/or in vitro/ex vivo tissue engineering, in combination with biomimetic/biocompatible biomaterials and/or natural or recombinantly derived biologics.43 These cells may also be considered clinically for their ability to deliver genes or gene products. Immediate
References (93)
- et al.
Biomaterial challenges and approaches to stem cell use in bone reconstructive surgery
Drug Discov Today
(2004) Stem cells: Hype or hope?
Drug Discov Today
(2002)- et al.
Hematopoietic stem cells and microenvironment: The proliferation and differentiation of stromal cells
Crit Rev Oncol Hematol
(1995) - et al.
Multilineage mesenchymal differentiation potential of human trabecular bone-derived cells
J Orthop Res
(2002) - et al.
The “common stem cell” hypothesis re-evaluated: Human fetal bone marrow contains separate populations of hematopoietic and stromal progenitors
Blood
(1995) - et al.
Mesenchymal stem cells: Paradoxes of passaging
Exp Hematol
(2004) The mesengenic process
Clin Plast Surg
(1994)- et al.
Isolation and characterization of multipotential mesenchymal stem cells from feline bone marrow
Exp Hematol
(2002) - et al.
Culture expanded canine mesenchymal stem cells possess osteochondrogenic potential in vivo and in vitro
Cell Transplant
(1997) - et al.
Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies
Bone
(1992)